GlassScriptPhysician profile
Joseph C Yellin
NPI 1700892783
$5,864.86
in general payments reported to CMS, 2019-2025
28 companies · $505 in 2025
The $505 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $537 · 2020: $841 · 2021: $1,108 · 2022: $1,213 · 2023: $1,121 · 2024: $540 · 2025: $505.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,166.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,166.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,029.48 | 2021-2025 | Botox, Ubrelvy, Qulipta |
| Allergan, INC. | $1,005.61 | 2019-2022 | |
| Lilly USA, LLC | $402.04 | 2019-2023 | Emgality, Reyvow |
| Otsuka America Pharmaceutical, INC. | $371.87 | 2023-2025 | Rexulti, Nuedexta |
| Amgen INC. | $312.55 | 2019-2022 | |
| Biohaven Pharmaceuticals, INC. | $292.13 | 2020-2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $162.94 | 2022 | |
| Pfizer INC. | $144.81 | 2023-2024 | |
| Avanir Pharmaceuticals, INC. | $140.56 | 2019-2022 | |
| Neurocrine Biosciences, INC. | $119.28 | 2022-2025 | |
| Akcea Therapeutics, INC. | $99.13 | 2019-2021 | |
| Paladin Technology Solutions | $98.62 | 2023 | |
| Sumitomo Pharma America, INC. | $85.56 | 2024 | Aptiom |
| Amneal Pharmaceuticals LLC | $80.17 | 2022-2023 | Rytary, Lyvispah |
| Arbor Pharmaceuticals, INC. | $73.64 | 2019-2020 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $56.23 | 2020-2023 | Briviact |
| Acorda Therapeutics, INC | $54.03 | 2019 | |
| Eisai INC. | $51.46 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $49.63 | 2019 | |
| Biogen, INC. | $48.70 | 2020-2021 | |
| Avion Pharmaceuticals | $33.55 | 2023 | Dhivy |
| Lundbeck LLC | $29.04 | 2025 | Rexulti |
| Acadia Pharmaceuticals INC | $24.12 | 2022 | |
| Boston Scientific Corporation | $22.43 | 2019 | |
| Zyla Life Sciences, INC. | $22.17 | 2020 | |
| Bausch Health US, LLC | $19.89 | 2019 | |
| Upsher-Smith Laboratories LLC | $19.62 | 2019 | |
| Alexion Pharmaceuticals, INC. | $15.60 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Yellin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.